Atara Biotherapeutics (ATRA) Revenue (2021 - 2026)

Atara Biotherapeutics (ATRA) has reported Revenue for 6 consecutive years, with $630000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 96.42% year-over-year to $630000.0; the trailing twelve-month figure through Jun 2026 stood at $6.2 million (down 96.72% YoY), and the FY2025 full-year result was $120.8 million, down 6.33% from the prior year.
• Revenue advanced to $630000.0 in Q2 2026 per ATRA's latest filing, from $516000.0 in the prior quarter.
• Across five years, Revenue topped out at $98.1 million in Q1 2025 and bottomed at $248000.0 in Q4 2022.
• Historically, Revenue has averaged $17.9 million across 5 years, with a median of $4.4 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Revenue surged 2892.69% in 2024, then slumped 99.47% in 2026.
• Over 5 years, Revenue stood at $248000.0 in 2022, then surged by 1614.52% to $4.3 million in 2023, then jumped by 670.3% to $32.8 million in 2024, then sank by 95.13% to $1.6 million in 2025, then plunged by 60.5% to $630000.0 in 2026.
• According to Business Quant data, Revenue over the past three periods registered $630000.0, $516000.0, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.